The Importance of Metabolic and Proteomic Analyses in Identifying Treatment Pathways for Cancer Patients


In the second episode of this series, host and the CEO of TD2, Dr. Stephen Gately, sits down with Dr. Ed Weinstein, co-founder and CEO of Panome Bio, to discuss their important research on metabolomics and proteomics. They delve into the role of obesity in cancer development and response to immune checkpoint therapies, global metabolic analyses in combination with next-generation sequencing and more.

Listen Now


Get Started.

Have questions about how TD2 can assist with your regulatory needs? Reach out to our expert staff today to get started.